Fig. 5.

Pretreatment with the 12-/15-LOX–dependent AA metabolites 12-HETE and 15-HETE attenuates DPDPE-mediated anti-allodynia. Rats received intraplantar injections of vehicle (Veh), 12-HETE (0.1 µg), 15-HETE (0.1 µg), or 12-HETE and 15-HETE combined. After 45 minutes, rats were injected with Veh or BK (25 µg), and then 15 minutes later received coinjections of PGE₂ (0.3 µg) with DPDPE (20 µg). (A) PWL was measured before (baseline) and at 5-minute intervals after the PGE₂/DPDPE injection for 20 minutes. Data were evaluated for statistical differences with two-way analysis of variance (ANOVA), followed by Tukey’s post hoc analysis. (B) Area under the individual time-course curves (AUC) for each pretreatment condition. Data were evaluated for statistical differences with one-way ANOVA, followed by Dunnett’s post hoc analysis. Data represent mean ± S.E.M. of 6 (Veh-Veh pretreatment), 9 (Veh-BK pretreatment), 12 (12-HETE/BK pretreatment), 9 (15-HETE/BK pretreatment), or 4 (12- + 15-HETE/BK pretreatment) animals per group. *P < 0.05, ***P < 0.001 compared with Veh/Veh/DPDPE + PGE₂ (i.e., no pretreatment with BK). As shown in Supplemental Fig. 1 and 2, 12-HETE and 15-HETE did not alter either baseline PWL or PGE₂ -evoked PWL.